Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01903993
Title A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.